[Current aspects of the evaluation of ERBB2 activation in breast cancer. Therapeutic perspectives].
The ERBB2 (HER-2/neu) protooncogene encodes a transmembrane protein with an intracellular tyrosine kinase activity. It is principally activated by gene amplification and its product, the erbB2 protein, becomes oncogenic when overexpressed. Quantitative PCR is both a simple and reliable method for the evaluation of ERBB2 activation, whereas immunoenzymatic methods allow quantitative determination of erbB2 protein in tissue and sera. ERBB2 amplification and/or surexpression is actually recognized as a prognostic factor in breast cancer and would be predictive in the therapeutic response. It might lead also to new therapeutic modalities using specific targeted drugs.
Tse
C
C
Laboratoire de biochimie et de biologie moléculaire, Hôpital Tenon, Paris.
Brault
D
D
Etienne
J
J
D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000628:therapy; D005260:Female; D005544:Forecasting; D015972:Gene Expression Regulation, Neoplastic; D018734:Genes, erbB-2 / Q000235:genetics*; D005819:Genetic Markers; D006801:Humans; D016133:Polymerase Chain Reaction
D014408:Biomarkers, Tumor; D005819:Genetic Markers
Aspects actuels de l'évaluation de l'activation ERBB2 dans le cancer du sein. Perspectives thérapeutiques.